Biopharmaceutical firm ATAI Life Sciences joins the roster of companies with BTC Treasury approaches
Another company is elected to add bitcoin (BTC) to its balance.
Christian Angmayer, chairman of the biopharmaceutical company Atai Life Sciences (ATAI) has now announced that the company will develop its own approach to the Bitcoin treasury.
“During a time of continued inflation and market change, I found myself asking for an important question for biotech companies seeking to maintain and optimize the capital they had: can allocate a portion of cash cash in Bitcoin that will help maintain, optimize, and even extend the path of a company and therefore contribute to its success,” Angermayer wrote to the subtack.
The company first invests $ 5 million in Bitcoin, said Angermayer, while holding enough cash, short -term security and public equity for operating costs in 2027.
The pharmaceutical firm is the latest in a long line of corporations that seek to copy the Bitcoin wealth approach of Michael Saylor.
Atai briefly progressed when the news broke but it now dropped 2.8% for the day. After a short -top $ 87,000 night, Bitcoin retreated quickly, now changing hands to $ 83,900, less than 1% in the past 24 hours.
